Scheinman M M
Department of Medicine, University of California, San Francisco 94143-1354, USA.
J Cardiovasc Electrophysiol. 1995 Oct;6(10 Pt 2):914-9. doi: 10.1111/j.1540-8167.1995.tb00367.x.
More effective intravenous antiarrhythmic agents are required for treatment of patients with refractory malignant ventricular arrhythmias. More recently, a great deal of interest has been focused on use of intravenous amiodarone for these patients. Uncontrolled early studies showed that intravenous amiodarone was effective in 42% to 81% of treated patients. Recent large cooperative trials have documented the efficacy of intravenous amiodarone in these patients and have shown an efficacy comparable to bretylium in patients with refractory sustained ventricular tachycardia or fibrillation.
治疗难治性恶性室性心律失常患者需要更有效的静脉抗心律失常药物。最近，人们对静脉使用胺碘酮治疗这些患者产生了浓厚兴趣。早期的非对照研究表明，静脉使用胺碘酮在42%至81%的治疗患者中有效。最近的大型合作试验证实了静脉使用胺碘酮对这些患者的疗效，并表明在难治性持续性室性心动过速或颤动患者中，其疗效与溴苄铵相当。
